We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Delcath Systems Inc (DCTH) USD0.01

Sell:$7.33 Buy:$7.53 Change: $1.22 (13.36%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Change: $1.22 (13.36%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Change: $1.22 (13.36%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Delcath Systems, Inc. is an oncology company. The Company is focused on the treatment of primary and metastatic liver cancers. The Company is a specialty pharmaceutical and medical device company developing its products. The Company's lead product candidate is HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) is a drug/device combination product. HEPZATO is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The Company's focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.

Contact details

1633 Broadway Ste 22C
United States
+1 (212) 4892100

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$71.43 million
Shares in issue:
7.36 million
Health Care Equipment
United States
US dollar

Key personnel

  • Gerard Michel
    Chief Executive Officer, Director
  • John Purpura
    Chief Operating Officer, Executive Vice President - Global Head of Operations
  • Christine Padula
    Interim Principal Accounting Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.